Celldex Therapeutics Inc (CLDX)
27.78
-0.33 (-1.17%)
USD |
NASDAQ |
Oct 03, 16:00
27.78
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.299B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -47.93% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1565.03 |
| Price to Book Value | 3.559 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.64% |
News
Headline
Wire
Time (ET)
--SVB Securities Adjusts Celldex Therapeutics' Price Target to $64 From $68, Keeps Outperform Rating
MT Newswires
08/09 10:59
Yahoo
08/08 16:01
MT Newswires
07/21 10:30
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/28/2023* | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 11/09/2022* | -- | Results | Q3 2022 | -- | -0.57 | -- | |
| 08/08/2022 | -- | Results | Q2 2022 | -0.58 | -0.42 | -40.28% | |
| 05/05/2022 | -- | Results | Q1 2022 | -0.50 | -0.44 | -16.00% | |
| 02/28/2022 | -- | Results | Q4 2021 | -0.46 | -0.38 | -20.43% | |
| 02/28/2022 | 16:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 11/09/2021 | -- | Results | Q3 2021 | -0.37 | -0.35 | -7.41% | |
| 08/05/2021 | -- | Results | Q2 2021 | -0.34 | -0.40 | 15.70% |
*Estimated Date/Time
Earnings
Profile
Edit
| Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. |
| URL | https://www.celldex.com |
| Investor Relations URL | https://ir.celldex.com |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Nov. 09, 2022 (est.) |
| Last Earnings Release | Aug. 08, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of September 30, 2022.
Fundamentals
| Revenue (TTM) | 0.824M |
| Total Expenses (TTM) | 92.15M |
| Net Income (TTM) | -99.65M |
| Total Assets (Quarterly) | 402.96M |
| Total Liabilities (Quarterly) | 37.87M |
| Shareholders Equity (Quarterly) | 365.09M |
| Cash from Operations (TTM) | -77.67M |
| Cash from Investing (TTM) | -210.07M |
| Cash from Financing (TTM) | 272.70M |
Ratings
Profile
Edit
| Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. |
| URL | https://www.celldex.com |
| Investor Relations URL | https://ir.celldex.com |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Nov. 09, 2022 (est.) |
| Last Earnings Release | Aug. 08, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| CLDX Tweets |